Company Promoters:
Ravi Goenka & Yellow Stone Trust are the company promoters.
Company Details:-
Laxmi Organic is the only manufacturer of diketene derivatives in India with a market share of approximately 55 % of the Indian diketene derivatives market in terms of revenue in Fiscal 2020 and one of the largest portfolios of diketene products (source: Frost & Sullivan Report). Company’s products are currently divided into two broad categories, namely the Acetyl Intermediates and the Specialty Intermediates. The Acetyl Intermediates include ethyl acetate, acetaldehyde, fuel-grade ethanol and other proprietary solvents, while the Specialty Intermediates comprises of ketene, diketene derivatives namely esters, acetic anhydride, amides, arylides and other chemicals. Company’s products find application in various high-growth industries, including pharmaceuticals, agrochemicals, dyes & pigments, inks & coatings, paints, printing & packaging, flavours & fragrances, adhesives and other industrial applications.
Over the years, Laxmi Organic have significantly expanded their scale of operations and global footprint with customers in over 30 countries including China, Netherlands, Russia, Singapore, United Arab Emirates, United Kingdom and United States of America. Company have offices in Leiden (Netherlands), Shanghai (China) and Sharjah (United Arab Emirates) which enables them to assess international demand and increase their customer outreach thereby bolstering their product development initiatives. Company currently have two manufacturing facilities in Mahad, Maharashtra (the “Manufacturing Facilities”), with one facility dedicated to Acetyl Intermediates (the “AI Manufacturing Facility”) and another dedicated to Specialty
Intermediates (the “SI Manufacturing Facility”). They also have two distilleries located in Satara district (the “Jarandeshwar Distillery”) and Kolhapur district in Maharashtra (the “Panchganga Distillery”). Company have two Department of Scientific and Industrial Research, Government of India (“DSIR”) recognized research and development facilities, with state-of-the-art research and development infrastructure to synthesise specialty molecules and advanced intermediates (source: Frost & Sullivan Report).
Issue Details:
|
Issue
Period |
Monday,
March 15th, 2021 |
|
Wednesday,
March 17th, 2021. |
|
|
Price
Band |
Rs.129/- to Rs.130/- per equity
shares. |
|
Bid
Lot |
115 Equity share and in multiple
of 115 equity share thereafter. |
|
Issue
Size |
Rs.
600.00 Cr. |
|
Issue
break-up |
QIB
- 50 % of the offer - Rs. 300.00 Cr |
|
NIB
- 15 % of the offer - Rs. 90.00 Cr |
|
|
RET
- 35 % of the offer - Rs.
210.00 Cr |
|
|
Listing |
BSE
& NSE |
|
Registrar |
Link
Intime India Private Limited |
|
UPI |
All
Retail Applications through brokers are compulsorily in UPI Mode |
| Allotment Date | Mar 22, 2021 |
| Refund Initiation | Mar 23, 2021 |
| Credit of Shares to Demat A/c | Mar 24, 2021 |
| IPO Listing Date | Mar 25, 2021 |

0 ಕಾಮೆಂಟ್ಗಳು